Home・Listă Acțiuni・Moderna Inc

Moderna Inc

Închisă

SectorSănătate

56.94 3.32

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

55.11

Maxim

58.19

Indicatori cheie
By Trading Economics
Venit	561M -782M
Vânzări	-244M 145M
EPS	-1.97
Marjă de profit	-539.31
Angajați	4,700
EBITDA	554M -704M

Recomandări
By TipRanks
Recomandări	Neutru
Prognoză pe 12 luni	-11.28% downside

Dividende
By Acuity
Următoarele câștiguri	5 nov. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-194M 22B
Deschiderea anterioară	53.62
Închiderea anterioară	56.94

Sentimentul știrilor

By Acuity

29%

71%

110 / 340 Clasament în Healthcare

Moderna Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

4 aug. 2026, 20:07 UTC

Social Media

News

Moderna initiates Phase 1 trial for mRNA-1469 vaccine, backed by CEPI's $50 million funding. Shares are higher despite earlier session pullback.

3 aug. 2026, 20:03 UTC

News

Moderna Inc. shares are advancing as Citigroup raises its price target to $60 amid broader market strength and gains in major tech stocks.

31 iul. 2026, 23:26 UTC

Moderna Inc. shares are lower in after-hours trading, continuing a decline from Friday's close without any specific news to explain the movement.

30 iul. 2026, 23:51 UTC

Moderna Inc shares are higher in after-market trading, driven by a significant advance in the overall market, despite earlier fluctuations during the session.

29 iul. 2026, 23:51 UTC

Moderna Inc is rising in after-market trading, aligning with broader market gains. The stock showed volatility earlier in the session without specific news driving the move.

28 iul. 2026, 18:36 UTC

Moderna Inc shares are lower today, continuing a decline from Monday's close amid risk-off sentiment following significant declines in Asian markets.

27 iul. 2026, 19:07 UTC

Social Media

Moderna Inc. is advancing as it initiates a Phase 1 trial for its mRNA-4200 cancer vaccine, with the first U.S. participant dosed on July 16, 2026.

24 iul. 2026, 19:03 UTC

Social Media

News

Moderna Inc shares are lower today amid mixed options sentiment and increased demand for downside protection ahead of its upcoming earnings report.

23 iul. 2026, 19:56 UTC

Social Media

News

Moderna Inc shares are lower, trading around $57.25, as options activity remains light. An mRNA vaccine is set for a Phase 1 trial in August.

21 iul. 2026, 20:07 UTC

News

Social Media

Goldman Sachs raised Moderna's price target to $49.00 while maintaining a Neutral rating, reflecting a more favorable outlook on the company's valuation. Shares are higher today.

20 iul. 2026, 23:46 UTC

Moderna Inc shares are lower in after-market hours amid rising Treasury yields and broader market trends, with no specific company news identified.

Comparație

Modificare preț

Moderna Inc Așteptări

Obiectiv de preț

By TipRanks

-11.28% jos

Prognoză pe 12 luni

Medie 48.92 USD -11.28%

Maxim 77 USD

Minim 39 USD

În baza a 15 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruModerna Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

15 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 15 analiști care au acordat evaluări ale acțiunilor Moderna Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

110 / 340 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Moderna Inc

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.